Beta-Blockers Found Ineffective for Heart Attack Survivors

Key Findings from the REBOOT Trial

According to НВ — Техно: The international REBOOT clinical trial has concluded that beta-blockers are ineffective and potentially harmful for patients who maintain normal heart function after an uncomplicated heart attack. These results were presented at the European Society of Cardiology Congress in Madrid and published in The New England Journal of Medicine.

Led by renowned cardiologists Valentin Fuster and Borja Ibáñez, the study analyzed data from 8,505 patients across 109 hospitals in Spain and Italy. Participants all had normal cardiac function following an uncomplicated myocardial infarction and were divided into two groups: one receiving beta-blockers and the other not. The follow-up period lasted four years.

The findings were striking: the medications showed no significant reduction in mortality rates, recurrent heart attacks, or hospitalizations. This suggests that modern medicine, thanks to technologies enabling rapid restoration of blood vessel patency, has reduced the need for beta-blocker use.

Impact on Patients and Updated Recommendations

A secondary analysis published in the European Heart Journal reveals that women with an ejection fraction of 50% or higher who took beta-blockers experienced a 2.7% increase in absolute mortality risk over 3.7 years of follow-up. No such negative effect was observed in men. Despite this, over 80% of patients are still discharged from hospitals with a beta-blocker prescription.

Discontinuing ineffective treatments could help patients avoid side effects such as:

• chronic fatigue
• bradycardia
• sexual dysfunction

The study authors emphasized that patients should not stop taking medications on their own, but cardiac therapy must become significantly more personalized for each individual.

The REBOOT trial results could have major implications for clinical cardiology practice, as they highlight the need to rethink treatment approaches for post-heart attack patients. This may lead to changes in guidelines for prescribing beta-blockers, ultimately improving the safety and effectiveness of care. Furthermore, a stronger emphasis on personalized therapy could enhance patient outcomes by reducing risks and side effects tied to ineffective drugs.